Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers

Summary

The purpose of this study is to determine the safety profile and maximum tolerable dose (MTD) of GBR 1302 monotherapy in subjects with HER2 positive cancers

Timeline

Start

2016-05

Primary completion

2019-05

Completion

2019-05

Outcome

Outcome not reported

Stopped: “Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention”

Drugs

Indications